NFKB1 and neoplasm: Similarly, combining hEGFR Ab (Cetuximab) with p50-IMC increased localization of p50-IMC to MC/hEGFR tumors in NSG mice, when administered after a dose of 5-FU, with total IMC per mg of tumor reaching significance (Fig. 7).